Job Description

Job Overview

The Deputy Chief Manager of Learning and Development (L&D) at Piramal Pharma will play a key role in


enhancing the organization's learning ecosystem. The role holder will be responsible for running 1 2


Functional Academies, building and revamping the digital learning architecture, and driving Leadership


Academy initiatives. This includes transitioning to a new Learning Experience Platform (LXP) to replace the


existing Learning Management System (LMS), augmenting digital learning resources by introducing more


content providers, and managing leadership development programs. The role will also involve learning


analytics, in partnership with the HR Analytics team, to develop an L&D dashboard and drive mandatory


compliance modules. The individual will foster and sustain a culture of continuous learning by leveraging


both digital and traditional platforms.





KEY STAKEHOLDERS: INTERNALHR Leadership Team , Business HR Heads, HR Business Partners, COE Heads, Business Learning Leaders, Department Heads of various Corporate Functions, Learners and Top Talent Groups





KEY STAKEHOLDERS: EXTERNALConsulting firms of repute, training providers, executive education and continuing education providers, learning technology vendors, learning content providers & external professional bodies





REPORTING STRUCTURE:


Deputy Chief Manager Learning & Development will report to the General Manager Head of Learning and


Development CoE

Experience

4 to 8 years experience in Learning & Development / Leadership Development / TM / OD

Competencies

Learning & Development Expertise:


Instructional design & Facilitation Skills , Digital Learning Solutions:


Experience with Learning Experience Platforms (LXP), e learning systems, and managing digital content


providers, Leadership Development: Proven track record in running leadership programs, including


designing and executing, Building Continuous Learning Culture: Passion for driving learning and


development across an organization and engaging employees through innovative learning experiences.


Learning Analytics, Project Management, Stakeholder Management, Communication & Influence.



In the three decades of its existence, Piramal Group has pursued a twin strategy of both organic and inorganic growth.
Driven by its core values, Piramal Group steadfastly pursues inclusive growth, while adhering to ethical and values-driven practices.

Equal employment opportunity

Piramal Group is proud to be an Equal Employment Opportunity and Affirmative Action employer. We do not discriminate based upon race, ethnicity, religion, color, national origin, gender (including pregnancy, childbirth, or related medical conditions), sexual orientation, gender identity, gender expression, age, status as a protected veteran, status as an individual with a disability, genetics, or other applicable legally protected characteristics.



We base our employment decisions on merit considering qualifications, skills, performance, and achievements. We endeavor to ensure that all applicants and employees receive equal opportunity in personnel matters, including recruitment, selection, training, placement, promotion, demotion, compensation and benefits, transfers, terminations, and working conditions, including reasonable accommodation for qualified individuals with disabilities as well as individuals with needs related to their religious observance or practice.

Piramal Pharma Limited (PPL) offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 15 global facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organization; Piramal Critical Care (PCC), a Complex Hospital Generics business, and the India Consumer Healthcare business selling over-the-counter products.


PPS offers end-to-end development and manufacturing solutions through a globally integrated network of facilities across the drug life cycle to innovators and generic companies. PCC's complex hospital product portfolio includes inhalation anaesthetics, intrathecal therapies for spasticity and pain management, injectable pain and anaesthetics, injectable anti-infectives, and other therapies. The Indian Consumer Healthcare business is among the leading players in India in the self-care space, with established brands in the Indian consumer healthcare market. In addition, PPL has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market. In October 2020, the company received a growth equity investment from the Carlyle Group.